However, TEPP-46 treatment did not alter the expression of HIF-1α and PKM2, the level of glycolytic activity, or the induction of type I IFN in tumor-infiltrating STING-deficient DCs (Figure 7, H–J). This evidence concerns the gene HIF1A and neoplasm.